181 related articles for article (PubMed ID: 35789054)
1. New Opportunities for the Utilization of the Sulfoximine Group in Medicinal Chemistry from the Drug Designer's Perspective.
Lücking U
Chemistry; 2022 Oct; 28(56):e202201993. PubMed ID: 35789054
[TBL] [Abstract][Full Text] [Related]
2. Sulfoximines: a neglected opportunity in medicinal chemistry.
Lücking U
Angew Chem Int Ed Engl; 2013 Sep; 52(36):9399-408. PubMed ID: 23934828
[TBL] [Abstract][Full Text] [Related]
3. Application of sulfoximines in medicinal chemistry from 2013 to 2020.
Han Y; Xing K; Zhang J; Tong T; Shi Y; Cao H; Yu H; Zhang Y; Liu D; Zhao L
Eur J Med Chem; 2021 Jan; 209():112885. PubMed ID: 33227576
[TBL] [Abstract][Full Text] [Related]
4. Sulfoximines as Rising Stars in Modern Drug Discovery? Current Status and Perspective on an Emerging Functional Group in Medicinal Chemistry.
Mäder P; Kattner L
J Med Chem; 2020 Dec; 63(23):14243-14275. PubMed ID: 32870008
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in epigenetic proteolysis targeting chimeras (Epi-PROTACs).
Tomaselli D; Mautone N; Mai A; Rotili D
Eur J Med Chem; 2020 Dec; 207():112750. PubMed ID: 32871345
[TBL] [Abstract][Full Text] [Related]
6. Sulfoximines from a Medicinal Chemist's Perspective: Physicochemical and in vitro Parameters Relevant for Drug Discovery.
Frings M; Bolm C; Blum A; Gnamm C
Eur J Med Chem; 2017 Jan; 126():225-245. PubMed ID: 27821325
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and Transformations of NH-Sulfoximines.
Andresini M; Tota A; Degennaro L; Bull JA; Luisi R
Chemistry; 2021 Dec; 27(69):17293-17321. PubMed ID: 34519376
[TBL] [Abstract][Full Text] [Related]
8. Antibody-drug conjugates- stability and formulation.
Duerr C; Friess W
Eur J Pharm Biopharm; 2019 Jun; 139():168-176. PubMed ID: 30940541
[TBL] [Abstract][Full Text] [Related]
9. The Future of Medicinal Chemistry, PROTAC, and Undruggable Drug Targets.
Poso A
J Med Chem; 2021 Aug; 64(15):10680-10681. PubMed ID: 34296872
[TBL] [Abstract][Full Text] [Related]
10. The 17
Ciulli A; O'Connor S; Chung CW; Hartung IV; Testa A; Daniels DL; Heitman LH
ChemMedChem; 2023 Oct; 18(20):e202300464. PubMed ID: 37817354
[TBL] [Abstract][Full Text] [Related]
11. Covalent fragment approaches targeting non-cysteine residues.
Csorba N; Ábrányi-Balogh P; Keserű GM
Trends Pharmacol Sci; 2023 Nov; 44(11):802-816. PubMed ID: 37770315
[TBL] [Abstract][Full Text] [Related]
12. Increasing Complexity: A Practical Synthetic Approach to Three-Dimensional, Cyclic Sulfoximines and First Insights into Their in Vitro Properties.
Boulard E; Zibulski V; Oertel L; Lienau P; Schäfer M; Ganzer U; Lücking U
Chemistry; 2020 Apr; 26(19):4378-4388. PubMed ID: 31961028
[TBL] [Abstract][Full Text] [Related]
13. Emerging and Re-emerging Warheads for Targeted Covalent Inhibitors: An Update.
Hillebrand L; Liang XJ; Serafim RAM; Gehringer M
J Med Chem; 2024 May; 67(10):7668-7758. PubMed ID: 38711345
[TBL] [Abstract][Full Text] [Related]
14. Electrophilic warheads in covalent drug discovery: an overview.
Péczka N; Orgován Z; Ábrányi-Balogh P; Keserű GM
Expert Opin Drug Discov; 2022 Apr; 17(4):413-422. PubMed ID: 35129005
[TBL] [Abstract][Full Text] [Related]
15. Formulation development of antibody-drug conjugates.
Galush WJ; Wakankar AA
Methods Mol Biol; 2013; 1045():217-33. PubMed ID: 23913150
[TBL] [Abstract][Full Text] [Related]
16. Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 1: Exploration of Antibody Linker, Payload Loading, and Payload Molecular Properties.
Dragovich PS; Pillow TH; Blake RA; Sadowsky JD; Adaligil E; Adhikari P; Bhakta S; Blaquiere N; Chen J; Dela Cruz-Chuh J; Gascoigne KE; Hartman SJ; He M; Kaufman S; Kleinheinz T; Kozak KR; Liu L; Liu L; Liu Q; Lu Y; Meng F; Mulvihill MM; O'Donohue A; Rowntree RK; Staben LR; Staben ST; Wai J; Wang J; Wei B; Wilson C; Xin J; Xu Z; Yao H; Zhang D; Zhang H; Zhou H; Zhu X
J Med Chem; 2021 Mar; 64(5):2534-2575. PubMed ID: 33596065
[TBL] [Abstract][Full Text] [Related]
17. Antibody-drug conjugates: recent advances in conjugation and linker chemistries.
Tsuchikama K; An Z
Protein Cell; 2018 Jan; 9(1):33-46. PubMed ID: 27743348
[TBL] [Abstract][Full Text] [Related]
18. Medicinal chemistry strategies for discovering antivirals effective against drug-resistant viruses.
Ma Y; Frutos-Beltrán E; Kang D; Pannecouque C; De Clercq E; Menéndez-Arias L; Liu X; Zhan P
Chem Soc Rev; 2021 Apr; 50(7):4514-4540. PubMed ID: 33595031
[TBL] [Abstract][Full Text] [Related]
19. Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical Biology.
Gehringer M; Laufer SA
J Med Chem; 2019 Jun; 62(12):5673-5724. PubMed ID: 30565923
[TBL] [Abstract][Full Text] [Related]
20. Antibody drug conjugates: design and selection of linker, payload and conjugation chemistry.
McCombs JR; Owen SC
AAPS J; 2015 Mar; 17(2):339-51. PubMed ID: 25604608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
